Our results demonstrate that by targeting HO-1 in PC cells and thereby disrupting the heme degradation pathway, we can diminish cellular survival, enhance the response to chemotherapy under both normoxic and hypoxic conditions, and mitigate certain aspects of metastasis. Here, HMOX1 is linked to pachyonychia congenita.